Seminars in Nuclear Medicine
Volume 34, Issue 4 , Pages 242-253 , October 2004

Clinical use of positron emission tomography in the management of cutaneous melanoma

  • Kent P. Friedman, MD

      Affiliations

    • Department of Radiology, Johns Hopkins University Hospital, Baltimore, MD, USA.
    • ,
  • Richard L. Wahl, MD

      Affiliations

    • Department of Radiology, Johns Hopkins University Hospital, Baltimore, MD, USA.
    • Corresponding Author InformationAddress reprint requests to Richard L.Wahl, MD, Department of Radiology, Johns Hopkins University Hospital, 601 North Caroline Street, Room 3223, Baltimore, MD 21287-0817.

References 

  1. Cancer Facts & Figures 2004, in American Cancer Society, Surveillance Research . Atlanta, GA: American Cancer Society; 2004;
  2. McKinnon JG , Yu XQ , McCarthy WH , et al.   Prognosis for patients with thin cutaneous melanoma (long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit) . Cancer . 2003;98:1223–1231
  3. Kalady MF , White RR , Johnson JL , et al.   Thin melanomas (Predictive lethal characteristics from a 30-year clinical experience) . Ann Surg . 2003;238:528–535 discussion 535–537
  4. Essner R . Surgical treatment of malignant melanoma . Surg Clin North Am . 2003;83:109–156
  5. Sondak VK , Sosman JA . Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine (Melacine) . Semin Cancer Biol . 2003;13:409–415
  6. Balch CM , Buzaid AC , Soong SJ , et al.   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma . J Clin Oncol . 2001;19:3635–3648
  7. Buzaid AC , Ross MI , Balch CM , et al.   Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system . J Clin Oncol . 1997;15:1039–1051
  8. Acland KM , O’Doherty MJ , Russell-Jones R . The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma . J Am Acad Dermatol . 2000;42:606–611
  9. Edwards MJ , Martin KD , McMasters KM . Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma . Surg Oncol . 1998;7:51–57
  10. Gershenwald JE , Thompson W , Mansfield PF , et al.   Multi-institutional melanoma lymphatic mapping experience (the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients) . J Clin Oncol . 1999;17:976–983
  11. Terhune MH , Swanson N , Johnson TM . Use of chest radiography in the initial evaluation of patients with localized melanoma . Arch Dermatol . 1998;134:569–572
  12. Rossi CR , Mocellin S , Scagnet B , et al.   The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients . J Surg Oncol . 2003;83:80–84
  13. Buzaid AC , Sandler AB , Mani S , et al.   Role of computed tomography in the staging of primary melanoma . J Clin Oncol . 1993;11:638–643
  14. Kuvshinoff BW , Kurtz C , Coit DG . Computed tomography in evaluation of patients with stage III melanoma . Ann Surg Oncol . 1997;4:252–258
  15. van den Brekel MW , Pameijer FA , Koops W , et al.   Computed tomography for the detection of neck node metastases in melanoma patients . Eur J Surg Oncol . 1998;24:51–54
  16. Heaston DK , Putman CE , Rodan BA , et al.   Solitary pulmonary metastases in high-risk melanoma patients (a prospective comparison of conventional and computed tomography) . Am J Roentgenol . 1983;141:169–174
  17. Silverman PM , Heaston DK , Korobkin M , et al.   Computed tomography in the detection of abdominal metastases from malignant melanoma . Invest Radiol . 1984;19:309–312
  18. Yang M , Martin DR , Karabulut N , et al.   Comparison of MR and PET imaging for the evaluation of liver metastases . J Magn Reson Imaging . 2003;17:343–349
  19. Wahl RL , Hutchins GD , Buchsbaum DJ , et al.   18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts . Feasibility studies for cancer imaging with positron-emission tomography. Cancer . 1991;67:1544–1550
  20. Kern KA . [14C]deoxyglucose uptake and imaging in malignant melanoma . J Surg Res . 1991;50:643–647
  21. Gritters LS , Francis IR , Zasadny KR , et al.   Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma . J Nucl Med . 1993;34:1420–1427
  22. Wagner JD , Schauwecker DS , Davidson D , et al.   FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume . J Surg Oncol . 2001;77:237–242
  23. Wagner JD , Schauwecker D , Hutchins G , et al.   Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma . J Surg Oncol . 1997;64:181–189
  24. Rinne D , Baum RP , Hor G , et al.   Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography (results of a prospective study of 100 patients) . Cancer . 1998;82:1664–1671
  25. Macfarlane DJ , Sondak V , Johnson T , et al.   Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma . J Clin Oncol . 1998;16:1770–1776
  26. Wagner JD , Schauwecker D , Davidson D , et al.   Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy . J Clin Oncol . 1999;17:1508–1515
  27. Acland KM , Healy C , Calonje E , et al.   Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma . J Clin Oncol . 2001;19:2674–2678
  28. Belhocine T , Pierard G , De Labrassinne M , et al.   Staging of regional nodes in AJCC stage I and II melanoma (18FDG PET imaging versus sentinel node detection) . Oncologist . 2002;7:271–278
  29. Fink AM , Holle-Robatsch S , Herzog N , et al.   Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II . Melanoma Res . 2004;14:141–145
  30. Schafer A , Herbst RA , Beiteke U , et al.   [Sentinel lymph node excision (SLNE) and positron emission tomography in the staging of stage I-II melanoma patients] . Hautarzt . 2003;54:440–447
  31. Mijnhout GS , Hoekstra OS , van Lingen A , et al.   How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning (the case of lymph node staging in melanoma) . J Clin Pathol . 2003;56:283–286
  32. Longo MI , Lazaro P , Bueno C , et al.   Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients . Dermatol Surg . 2003;29:245–248
  33. Hafner J , Schmid MH , Kempf W , et al.   Baseline staging in cutaneous malignant melanoma . Br J Dermatol . 2004;150:677–686
  34. Havenga K , Cobben DC , Oyen WJ , et al.   Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma . Eur J Surg Oncol . 2003;29:662–664
  35. Wagner JD , Davidson D , Coleman JJ , et al.   Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma . Ann Surg Oncol . 1999;6:398–404
  36. NCD for Positron Emission Tomography (PET) Scans (50-36), in Medicare Coverage Database. 2004
  37. Stas M , Stroobants S , Dupont P , et al.   18-FDG PET scan in the staging of recurrent melanoma (additional value and therapeutic impact) . Melanoma Res . 2002;12:479–490
  38. Blessing C , Feine U , Geiger L , et al.   Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma . Arch Dermatol . 1995;131:1394–1398
  39. Crippa F , Leutner M , Belli F , et al.   Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma . J Nucl Med . 2000;41:1491–1494
  40. Gulec SA , Faries MB , Lee CC , et al.   The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma (impact on surgical decision making) . Clin Nucl Med . 2003;28:961–965
  41. Dietlein M , Krug B , Groth W , et al.   Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma (a comparison of ultrasonographic and radiological methods of diagnosis) . Nucl Med Commun . 1999;20:255–261
  42. Tyler DS , Onaitis M , Kherani A , et al.   Positron emission tomography scanning in malignant melanoma . Cancer . 2000;89:1019–1025
  43. Steinert HC , Huch Boni RA , Buck A , et al.   Malignant melanoma (staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose) . Radiology . 1995;195:705–709
  44. Holder WD , White RL , Zuger JH . Effectiveness of positron emission tomography for the detection of melanoma metastases . Ann Surg . 1998;227:764–769 discussion 769–771
  45. Eigtved A , Andersson AP , Dahlstrom K , et al.   Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma . Eur J Nucl Med . 2000;27:70–75
  46. Swetter SM , Carroll LA , Johnson DL , et al.   Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients . Ann Surg Oncol . 2002;9:646–653
  47. Dalrymple-Hay MJ , Rome PD , Kennedy C . Pulmonary metastatic melanoma—the survival benefit associated with positron emission tomography scanning . Eur J Cardiothorac Surg . 2002;21:611–614 discussion 614–615
  48. Krug B , Dietlein M , Groth W , et al.   Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods . Acta Radiol . 2000;41:446–452
  49. Mercier GA , Alavi A , Fraker DL . FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma (Preliminary results) . Clin Nucl Med . 2001;26:832–836
  50. Lindholm P , Leskinen S , Nagren K , et al.   Carbon-11-methionine PET imaging of malignant melanoma . J Nucl Med . 1995;36:1806–1810
  51. Mishima Y , Imahori Y , Honda C , et al.   In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue . J Neurooncol . 1997;33:163–169
  52. Dimitrakopoulou-Strauss A , Strauss LG , Burger C . Quantitative PET studies in pretreated melanoma patients (a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis) . J Nucl Med . 2001;42:248–256
  53. Graham MM . Combined 18F-FDG-FDOPA tumor imaging for assessing response to therapy . J Nucl Med . 2001;42:257–258
  54. Cobben DC , Jager PL , Elsinga PH , et al.   3′-18F-fluoro-3′-deoxy-L-thymidine (a new tracer for staging metastatic melanoma?) . J Nucl Med . 2003;44:1927–1932
  55. Sadzot B , Sheldon J , Flesher J , et al.   Tracers for imaging melanin with positron emission tomography . Synapse . 1999;31:5–12
  56. Froidevaux S , Calame-Christe M , Schuhmacher J , et al.   A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases . J Nucl Med . 2004;45:116–123
  57. Schoder H , Larson SM , Yeung HW . PET/CT in oncology (integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies) . J Nucl Med . 2004;45(suppl 1):72S–81S
  58. Mijnhout GS , Hoekstra OS , van Tulder MW , et al.   Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients . Cancer . 2001;91:1530–1542
  59. Prichard RS , Hill AD , Skehan SJ , et al.   Positron emission tomography for staging and management of malignant melanoma . Br J Surg . 2002;89:389–396

PII: S0001-2998(04)00039-X

doi: 10.1053/j.semnuclmed.2004.06.001

Seminars in Nuclear Medicine
Volume 34, Issue 4 , Pages 242-253 , October 2004

Article Tools

* Image Usage & Resolution